Aytu Biopharma Inc reports results for the quarter ended in March - Earnings Summary

Aytu Biopharma

11/05/2023 22:53

* Aytu Biopharma Inc  AYTU.OQ  reported a quarterly adjusted
loss
of $1.93​​ per share for the quarter ended in March. The lone
analyst forecast for the quarter was for a loss of 63 cents per
share.
    * Revenue fell 6.1% to $22.73 million from a year ago;
analysts
expected $28.00 million. 
    * Aytu Biopharma Inc's reported EPS for the quarter was a
loss of
$1.93​.
    * The mean earnings estimate of analysts had risen by
about 37% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aytu Biopharma Inc shares had fallen by 5.8% this
quarter and
lost 44.2% so far this year.
    * The company reported a quarterly loss of $7.2 million.
    * Wall Street's median 12-month price target for Aytu
Biopharma
Inc is $70.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 09:53 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.63          -1.93          Missed
 Dec. 31 2022      -1.60          -1.31          Beat
 Sep. 30 2022      -3.60          -1.20          Beat
 Jun. 30 2022      -7.40          -9.80          Missed